Alternate Access Transcatheter Aortic Valve Replacement (TAVR): A single-sites experience with a viable treatment option for extreme risk patients Zachary.

Slides:

Advertisements

Similar presentations

TCT 2011 | San Francisco, CA | November 10, 2011 Two-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe.

Advertisements

Types of AVR Examples of replacement aortic valves: a) shows an aortic homograft, b) and c) show a xenograft, d) shows a ball and cage valve, e) shows.

Transcatheter aortic valve replacement (tAVR) are emerging as a viable treatment option for severe aortic stenosis in patients with significant co-morbidities.

Demographic Analysis of a Single Center Transcatheter Aortic Valve Replacement Practice Reveals Racial Disparities in Access to New Medical Technologies.

BACKGROUND OBJECTIVES METHODS RESULTS CONCLUSIONS Increasing use of advanced radiology in the Emergency Department (ED) has been shown to increase ED length.

Transcatheter Aortic Valve Therapies

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

Nimesh D. Desai MD PHD, Alberto Pochettino MD, Wilson Szeto MD, William Moser RN, Kanika Gupta BA, Patrick Moeller BA, Joseph E. Bavaria MD Hospital of.

A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.

PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Postoperative Delirium is Associated with Increased Operative and One Year Mortality in Patients Treated with Surgical and Transcatheter Aortic Valve Replacement.

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

Techniques in Transapical AVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director:

TCT 2015 | San Francisco | October 15, 2015 Howard C. Herrmann, MD on behalf of The PARTNER II Trial Investigators SAPIEN 3: Evaluation of a Balloon- Expandable.

The Reoperative Aortic Root: Degenerative Failure vs. Infectious Destruction – Outcomes of The “True Redo-Root” Reconstruction Rita K. Milewski, Arminder.

EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.

Martin B. Leon, M.D., Craig R. Smith, M.D., Michael Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat.

TriGuard Device for Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Multicenter Real-World Experience Masieh Abawi, Ermela.

New Data from The PARTNER Trial

The Journal of Thoracic and Cardiovascular Surgery

Volume 385, Issue 9986, Pages (June 2015)

The American Journal of Medicine

Are we ready to perform TAVI in Intermediate Risk Patients?

J. Matthew Brennan, MD, MPH Duke University School of Medicine

TAVR-Endocarditis Tarek Chami, MD

Adherence to the Labeling

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.

Joseph E. Bavaria, M.D. Roberts-Measey Professor and

TAVR – The Trans-carotid Approach

Fast-Track General Anesthesia for Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement Results In Shorter Intensive Care Unit and Hospital.

From: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve ReplacementA Systematic Review and Meta-analysis Ann Intern Med. 2016;165(5):

TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.

University of Pennsylvania

Ten-year trends in heart valve replacement operations

Jay Giri, MD, MPH Massachusetts General Hospital Boston, MA

Is Open Heart Surgery Too Risky For You? Opt for a Minimally Invasive Procedure.

Risk Stratification of Severe, Symptomatic Aortic Stenosis Patients

Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry

Transcatheter and Surgical Aortic Valve Replacement in Dialysis Patients: A Propensity- Matched Comparison Dale M. Kobrin, BA, Fenton H. McCarthy, MD,

Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators

A comprehensive review of the PARTNER trial

Median total new lesion volume

Arman Kilic, MD, Mary A. Siki, BS, Wilson Y. Szeto, MD, Joseph E

The Carotid Artery as a Preferred Alternative Access Route for Transcatheter Aortic Valve Replacement Eric B. Kirker, MD, Robert W. Hodson, MD, Kateri.

Impact of Preoperative Chronic Kidney Disease in 2,531 High-Risk and Inoperable Patients Undergoing Transcatheter Aortic Valve Replacement in the PARTNER.

Management of High-Risk Patients With Aortic Stenosis and Coronary Artery Disease Daniel Wendt, MD, Philipp Kahlert, MD, Tim Lenze, Markus Neuhäuser,

Ten-year trends in heart valve replacement operations

The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons.

Transapical Aortic Valve Replacement for Severe Aortic Stenosis: Results From the Nonrandomized Continued Access Cohort of the PARTNER Trial Todd M.

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.

The Progression of a Transcatheter Aortic Valve Program: A Decision Analysis of More Than 680 Patient Referrals Joseph E. Bavaria, MD, Wilson Y. Szeto,

Learning Alternative Access Approaches for Transcatheter Aortic Valve Replacement: Implications for New Transcatheter Aortic Valve Replacement Centers

Transcatheter Aortic Valve Replacement Outcomes in Nonagenarians Stratified by Transfemoral and Transapical Approach Christian McNeely, MD, Alan Zajarias,

Impact of Transcatheter Technology on Surgical Aortic Valve Replacement Volume, Outcomes, and Cost Robert B. Hawkins, MD, Emily A. Downs, MD, Lily E.

Vinod H. Thourani, MD, Hanna A

Bartosz Rylski, MD, Nimesh D. Desai, MD, PhD, Joseph E

Michele Gallo, MD, Gino Gerosa, MD

Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients on Maintenance Dialysis Fahad Alqahtani, MD, Sami Aljohani, MD, Khaled Boobes,

Alternative access for balloon-expandable transcatheter aortic valve replacement: Comparison of the transaortic approach using right anterior thoracotomy.

Vinod H. Thourani, MD, Hanna A

Aortic and Mitral Valve Replacement Versus Transcatheter Aortic Valve Replacement in Propensity-Matched Patients Fenton H. McCarthy, MD, Nimesh D. Desai,

Conventional redo biological valve replacement over 20 years: Surgical benchmarks should guide patient selection for transcatheter valve-in-valve therapy

Outcomes of Patients With Severe Chronic Lung Disease Who Are Undergoing Transcatheter Aortic Valve Replacement Rakesh M. Suri, MD, DPhil, Brian C. Gulack,

Intermediate Clinical and Hemodynamic Outcomes After Transcatheter Aortic Valve Implantation Augusto D’Onofrio, MD, PhD, Michela Facchin, MD, Laura Besola,

Thomas A. Treibel et al. JACC 2018;71:

Procedural Characteristics

Commentary: When a choice is not an echo

A. Procopi, N. Procopi, JP Collet, O. Barthelemy, P. Leprince, R

Presentation transcript:

Alternate Access Transcatheter Aortic Valve Replacement (TAVR): A single-sites experience with a viable treatment option for extreme risk patients Zachary Fox, Lauren DiBiase, Wilson Szeto, Saif Anwaruddin, Elizabeth Walsh, Robert Li, Howard Herrmann, Joseph Bavaria The University of Pennsylvania

Objectives The outcomes and effectiveness of Transcatheter Aortic Valve Replacement (TAVR) surgery in inoperable extreme risk patients (PARTNER TRIAL: Cohort B) is well established. However, the trial excluded patients without transfemoral access and the results in this population undergoing alternative access TAVR have varied. We examined our single-center results in extreme risk patients undergoing TAVR via the transapical (TA) and transaortic (TAO) approach.

Methods In 2012, 83 patients designated as Cohort B had alternative access TAVR via transapical approach (TA), n=71 or transaortic (TAO), n=12. This database was prospectively maintained.

Pre-Operative Demographics n=83(%) Males44 (53.0%) NYHA III or IV79 (95.2%) History of CVA/TIA11(13.3%) Carotid Artery Disease21 (25.3%) Coronary Artery Disease58 (69.9%) COPD27 (32.5%) Average STS7.9±5.3% Average Age83.7±6.2 years Results Post-Operative ResultsResults Average Length of Hospital Stay10.8±8.6 days 30 day & in-Hospital Stroke4 (4.2%) 30 day & in-Hospital Mortality11 (13.3%)

Conclusion Due to the nature of these extreme risk patients, we propose that alternative access TAVR should be offered to Cohort B patients, ideally to be performed at high volume TAVR centers. Further follow-up will attest to the potential improvement in morbidity and mortality in this extreme risk cohort, as compared to the natural progression of critical aortic stenosis.